Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AeroFact aerosolized surfactant pilot study in preterm infants with respiratory distress syndrome
ACTRN12617001458325Phase 2Completed
- Sponsor
- CPR Pharma Services
- Start
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of calfactant in respiratory distress syndrome (RDS) (2 arms), sponsored by CPR Pharma Services. Primary endpoints: Change from baseline in oxygenation indices, Change from baseline in vital signs and 1 more. Started Nov 2017; status: completed.
02
Drugs
calfactant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on ACTRN12617001458325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001458325.